RTTNews | Jun 21, 2021 07:57AM EDT

07:57 Monday, June 21, 2021 (RTTNews.com) - Anavex Life Sciences Corp. (AVXL) Monday announced positive results from the U.S. Phase 2 study of ANAVEX 2-73 (blarcamesine), the company's drug candidate for the treatment of female adults with Rett syndrome.

Treatment with ANAVEX 2-73 resulted in increase in the mRNA expression of SIGMAR1, that significantly correlated with improvements in the two primary clinical efficacy endpoints, the company said.

Rett syndrome is a chronic Central nervous system (CNS) disease caused by a spontaneous mutation of one gene, MECP2.

The company said it is planning to meet with the FDA to discuss the approval pathway for ANAVEX 2-73.

Read the original article on RTTNews ( https://www.rttnews.com/3203705/anavex-life-sciences-announces-positive-results-from-anavex-2-73-study-for-rett-syndrome-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved